ArticleHematological oncology2026

UMG1 Defines a Targetable Subset of T-Cell Lymphomas and Enables Precision Immunotherapy With a First-in-Class CD3ε Bispecific Engager.

Daniele Caracciolo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.